64 results
8-K
EX-10.1
IPIX
Innovation Pharmaceuticals Inc.
15 Jun 22
Entry into a Material Definitive Agreement
4:00pm
, officers and directors and reimbursement of business expenses incurred in the course of rendering services to the Company.
2. Closings of Issue … , (outside legal counsel for the Lead Purchaser), incurred in connection with the investment contemplated herein; provided however, that such reimbursement
8-K
EX-10.1
19vhuguxby icxbx
10 Dec 20
Entry into a Material Definitive Agreement
12:00am
424B5
6bxu0ln6 hnt8
10 Dec 20
Prospectus supplement for primary offering
12:00am
8-K
EX-10.1
lho ig8ovkj
4 Aug 20
Innovation Pharmaceuticals and U.S. Regional Biocontainment Laboratory Nearing Completion of Brilacidin Anti-SARS-CoV-2 (COVID-19) In Vitro Testing
9:29am
424B3
wbfy9oog56d
26 Dec 19
Prospectus supplement
5:18pm
8-K
EX-10.1
c9bie4johdr93yhmz
26 Dec 19
Entry into a Material Definitive Agreement
5:16pm
POS AM
yau6ptdag066qkf
17 Oct 19
Prospectus update (post-effective amendment)
5:23pm
POS AM
8inagif0ftl
20 Sep 19
Prospectus update (post-effective amendment)
4:35pm
PRE 14A
9b2r6wj3ym1r2 92
2 Aug 19
Preliminary proxy
4:28pm
8-K
EX-10.1
dj1jcnnjtz o87di
22 Jul 19
Entry into a Material Definitive Agreement
9:30am
8-K
EX-10.1
klfs6ycqnm
10 May 19
Entry into a Material Definitive Agreement
7:32am
424B5
ehwclayno2xqgu8sd7
10 May 19
Prospectus supplement for primary offering
7:31am
8-K
EX-10.1
61c66womg3t
9 Oct 18
Innovation Pharmaceuticals Secures Up to $10 Million in Additional Financing to Advance Clinical Pipeline
6:52am